SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AutoImmune-AIMM
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Thomas Stewart who wrote (124)5/21/1997 2:40:00 PM
From: Dr. John M. de Castro   of 298
 
AIMM has a Phase II trial comparing Coloral treatment to a DMARD (hydroxychloroquine) in patients who were failing steroid treatment and had not yet been put on DMARD therapy. The results of this trial are due out in July. This is the most stringent of the three Phase II Coloral trials and the one I would have rated the least likely to succeed. However, should Coloral do well in this trial, I would expect a considerable uptick in AIMM value.

John de C
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News